Drug intelligence / Profile preview

SENS-08

Development stage: Preclinical
Lead developer: Sensorium Therapeutics

Overview

**SENS-08** is an early-stage program from Sensorium Therapeutics, a biotechnology company leveraging its Biodynamic Discovery Platform™ and SensAI™ to develop CNS therapies inspired by natural compounds. It targets **Alzheimer's disease** and represents one of multiple pipeline assets in discovery, alongside more advanced programs like SENS-01 (anxiety) and SENS-03 (drug-resistant epilepsy). Specific details on its mechanism of action, modality, or preclinical data are not publicly disclosed, positioning it as a preclinical candidate in the company's portfolio focused on brain and mental health conditions.[10]

Beyond the preview

Go deeper on SENS-08.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SENS-08.

Explore the full profile